BR112017007202A2 - receptores de célula t - Google Patents

receptores de célula t

Info

Publication number
BR112017007202A2
BR112017007202A2 BR112017007202-5A BR112017007202A BR112017007202A2 BR 112017007202 A2 BR112017007202 A2 BR 112017007202A2 BR 112017007202 A BR112017007202 A BR 112017007202A BR 112017007202 A2 BR112017007202 A2 BR 112017007202A2
Authority
BR
Brazil
Prior art keywords
tcrs
cells
cell receptors
nucleic acids
mage
Prior art date
Application number
BR112017007202-5A
Other languages
English (en)
Inventor
HAYES Conor
VOLKOV Arsen
Gerry Andrew
BORDER Ellen
Carter Edward
Original Assignee
Adaptimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptimmune Limited filed Critical Adaptimmune Limited
Publication of BR112017007202A2 publication Critical patent/BR112017007202A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção refere-se aos receptores de célula t (tcrs) que se ligam ao peptídeo restrito hla-a*02 glydgmehl (seq id nº: 1) derivado da proteína mage-a10. os tcrs da invenção demonstram excelentes perfis de especificidade para este epítopo de mage. também são fornecidos ácidos nucleicos codificando os tcrs, células engenhendradas para apresentar os tcrs, células abrigando vetores de expressão codificando os tcrs e composições farmacêuticas compreendendo os tcrs, ácidos nucleicos ou células da invenção.
BR112017007202-5A 2014-10-08 2015-10-08 receptores de célula t BR112017007202A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462061248P 2014-10-08 2014-10-08
GBGB1417803.2A GB201417803D0 (en) 2014-10-08 2014-10-08 T cell receptors
US62/061,248 2014-10-08
GB1417803.2 2014-10-08
PCT/GB2015/052938 WO2016055785A1 (en) 2014-10-08 2015-10-08 T cell receptors

Publications (1)

Publication Number Publication Date
BR112017007202A2 true BR112017007202A2 (pt) 2018-03-06

Family

ID=51947049

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007202-5A BR112017007202A2 (pt) 2014-10-08 2015-10-08 receptores de célula t

Country Status (16)

Country Link
US (1) US11203627B2 (pt)
EP (1) EP3204409A1 (pt)
JP (2) JP6751391B2 (pt)
KR (1) KR20170092535A (pt)
CN (1) CN107001443A (pt)
AU (2) AU2015329783A1 (pt)
BR (1) BR112017007202A2 (pt)
CA (1) CA2963332A1 (pt)
GB (1) GB201417803D0 (pt)
IL (1) IL251524B (pt)
MX (1) MX2017004559A (pt)
NZ (1) NZ731571A (pt)
RU (1) RU2017115932A (pt)
SG (1) SG11201701983WA (pt)
WO (1) WO2016055785A1 (pt)
ZA (1) ZA201701823B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
GB201616238D0 (en) * 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
AU2018334886A1 (en) * 2017-09-22 2020-04-09 WuXi Biologics Ireland Limited Novel bispecific polypeptide complexes
MX2020003536A (es) 2017-10-03 2020-09-14 Juno Therapeutics Inc Moleculas de union especifica a virus de papiloma humano (hpv).
CN109879957B (zh) * 2017-12-06 2022-03-18 香雪生命科学技术（广东）有限公司 针对prame的高亲和力t细胞受体
JP2021520202A (ja) * 2018-04-05 2021-08-19 ジュノー セラピューティクス インコーポレイテッド 組換え受容体を発現する細胞の作製方法および関連組成物
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
KR20220052910A (ko) * 2019-07-09 2022-04-28 메디진 이뮤노테라피스 게엠바하 Ｍａｇｅａ10 특이적 ｔ 세포 수용체 및 이의 용도
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
CN114057864B (zh) * 2020-07-30 2023-12-15 香雪生命科学技术（广东）有限公司 一种识别afp的高亲和力tcr
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CA3205810A1 (en) * 2020-12-22 2022-06-30 Amgen Inc. Mage-b2-specific t-cell receptors
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN118201941A (zh) 2021-10-29 2024-06-14 吉利德科学公司 Cd73化合物
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN117003855B (zh) * 2023-09-20 2024-02-23 广州市老人院 一种t细胞受体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511124D0 (en) * 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
JP2007032255A (ja) 2005-06-24 2007-02-08 Tokai Rika Co Ltd 車両用信号発信装置
WO2007032255A1 (ja) * 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
SG177025A1 (en) * 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
EP2598528A1 (en) 2010-07-28 2013-06-05 Immunocore Ltd. T cell receptors
PT2618835T (pt) * 2010-09-20 2017-08-08 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Epítopos de célula t e recetores de célula t específicos de antigénio
DK2658872T3 (da) 2010-12-27 2020-10-12 Apo T B V Polypeptid, der binder aberrerende celler og inducerer apoptose
US20140378389A1 (en) * 2011-09-15 2014-12-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
WO2013057586A1 (en) * 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
AU2013308409A1 (en) * 2012-08-31 2015-03-26 University Of Birmingham Target peptides for immunotherapy and diagnostics
EP2951202B1 (en) * 2013-01-29 2020-04-08 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; High avidity binding molecules recognizing mage-a1
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
US11072660B2 (en) * 2016-10-03 2021-07-27 Juno Therapeutics, Inc. HPV-specific binding molecules

Also Published As

Publication number Publication date
IL251524A0 (en) 2017-05-29
MX2017004559A (es) 2018-02-23
EP3204409A1 (en) 2017-08-16
JP6751391B2 (ja) 2020-09-02
GB201417803D0 (en) 2014-11-19
CA2963332A1 (en) 2016-04-14
CN107001443A (zh) 2017-08-01
IL251524B (en) 2021-09-30
US20170218043A1 (en) 2017-08-03
JP2017533698A (ja) 2017-11-16
US20180208638A9 (en) 2018-07-26
US11203627B2 (en) 2021-12-21
NZ731571A (en) 2022-02-25
SG11201701983WA (en) 2017-04-27
KR20170092535A (ko) 2017-08-11
AU2015329783A1 (en) 2017-05-25
ZA201701823B (en) 2019-06-26
JP2020127406A (ja) 2020-08-27
AU2020203201A1 (en) 2020-06-04
WO2016055785A1 (en) 2016-04-14
RU2017115932A3 (pt) 2019-04-05
RU2017115932A (ru) 2018-11-12

Similar Documents

Publication Publication Date Title
BR112017007202A2 (pt) receptores de célula t
BR112018070625A2 (pt) receptores de células t
BR112018070600A2 (pt) receptores de células t
BR112018070637A2 (pt) receptores de células t
BR112018070260A2 (pt) receptores quiméricos e métodos de uso dos mesmos
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
NZ715038A (en) T cell receptors
BR112018070187A2 (pt) receptores quiméricos para flt3 e seus métodos de uso
MX2018012897A (es) Nuevos polipeptidos biespecificos contra cd137.
UA120917C2 (uk) Химерний білок фактора viii та його застосування
BR112017017884A2 (pt) switches transcricionais desencadeados por ligação e métodos de uso dos mesmos
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
TR201908550T4 (tr) Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
CL2012002095A1 (es) Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa
BR112018071466A2 (pt) novos peptídeos de ligação a cd1d imunogênicos
BR112014026644A2 (pt) peptídeos de agonistas de par4
WO2015107363A3 (en) Mycobacterial antigen composition
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
BR112016016737A2 (pt) Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma
AR101555A1 (es) ANTICUERPOS DIRIGIDOS AL RECEPTOR IIB DE Fc g Y AL RECEPTOR DE Fc e
BR112019007343A2 (pt) sequência de nucleotídeos expressando uma proteína de ancoragem de exossomo para uso como vacina
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
NZ731491A (en) Cd83 binding proteins and uses thereof
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
EA201390811A1 (ru) Пептиды tomm34 и содержащие их вакцины

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ADAPTIMMUNE LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2743 DE 01-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.